Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amarin Moves Beyond Bridge Financing With $70 Million Private Placement

This article was originally published in The Pink Sheet Daily

Executive Summary

Existing and new investors are drawn by the potential of a compound that would compete with statins in the dyslipidemia market.

You may also be interested in...



Amarin Accelerates Timeline For NDA Filing Of AMR101

Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.

Amarin Accelerates Timeline For NDA Filing Of AMR101

Positive results from a Phase III trial of Amarin Corporation's triglyceride-lowering drug AMR101 will allow the company to submit its NDA to FDA in 2011, a year ahead of schedule.

Amarin Shuffles Management Again, But Says Omega-3 Trial Results Are Near

On a quarterly earnings call, Amarin's new CEO says two Phase III trials of a drug to lower triglycerides will yield results a few months ahead of schedule.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel